base metals investing Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
base metals investing Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
base metals investing Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
base metals investing Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
base metals investing Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
base metals investing Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
base metals investing Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
base metals investing Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
base metals investing Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association 86th Scientific Sessions
base metals investing Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
base metals investing Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
